The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

at Regeneron, explained in the Hansoh deal release. “This is an exciting development in our obesity work at Regeneron, which also includes the muscle-sparing phase 2 COURAGE study investigating ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

The deal, announced Monday ... trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential future payments totaling up to $1.93 ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

The deal, announced Monday ... Ongoing studies include a Phase 3 obesity trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential ...

Regeneron’s trial shows semaglutide combos improve fat loss while preserving muscle in obesity treatment. Read more here.